Library
[New drugs; palifermin].
16 December 2006.
Cohen AF, Dubois EA, van Bronswijk H
View publicationPalifermin is a human keratinocyte growth factor that is produced in Escherichia coli by recombinant-DNA-technology. This substance protects against oral mucositis in adults undergoing myeloablative therapy. The safety of this product--being a growth factor --in the long term has not yet been shown. Adverse effects may occur in the skin and mucous membranes.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
